House FDA Hearing: No Plan for Domestic Drug Manufacturing
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
Sen. Tina Smith’s bill to provide $500 million in grants for domestic pharmaceutical manufacturers passes with flying colors and will be part of PREVENT Pandemics Act.
The House Committee on Energy and Commerce discussed FDA’s user fee budget and what can be done to reshore more of the pharmaceutical industry.
We Need to be Better at Industrial Policy By Amanda Mayoral, CPA Economist Industrial policy is critical to competing in a global economy and
Free trade loses out to a bigger government role in securing domestic supply chains of critical medication.
A House committee hearing on the impact of the supply crisis on small businesses left out one key solution: import less, make more here.
CPA’s report, titled “Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman,” details how a loophole
WASHINGTON — The Coalition for a Prosperous America (CPA) today released a new academic report that details how a loophole in the Hatch-Waxman Act has
An Indian drug market that’s been the subject of FDA warnings since 2017 is the apparent source of tainted medication sold in the U.S. and Canada. This is another example as to why we need to reshore critical supply of essential medication. Where is Congress?
Here we go again. Textile companies that spent money on retooling to make masks and hospital gowns now losing to China dumping PPE in the U.S.